Psoriasis is a common @entity272 characterized by hyperproliferation and incomplete differentiation of epidermal keratinocytes. @entity6339 plus UVA (PUVA) is one of the treatments proposed for this disease. We had reported previously that exposure of regular blood cultures from healthy donors to PUVA leads to chromosomal breakage via the formation of transferable clastogenic materials, a phenomenon inhibitable by @entity224 dismutase. In the present paper we show that these @entity4059 ( @entity4059 ) are also formed in vivo. The @entity4059 were found in about 50% of the @entity1569 @entity1 studied (14 out of 31). In PUVA-treated @entity1569 @entity1 , the clastogenic activity of the plasma increased significantly between the first and the last (16th) exposure to PUVA. We hypothesize that @entity4059 formation in @entity1569 is similar to that in other diseases accompanied by oxidative stress, in particular chronic @entity32 with @entity792 such as @entity1252 , @entity7087 , @entity309 and others. Increased @entity224 production by phagocytes, formation of lipid peroxidation products and release of cytokines are considered to be responsible for the @entity224 -stimulating and chromosome-damaging properties of @entity1 ' plasma. During PUVA therapy, @entity224 generated via the interaction of psoralen with UVA may contribute to @entity4059 formation in addition to @entity224 from inflammatory cells. An increased risk of @entity5 and @entity1778 is observed in diseases accompanied by @entity4059 formation. Therefore @entity4059 may contribute to the well-known risk of photocarcinogenesis by PUVA therapy. This additional risk may be preventable by antioxidants and @entity224 scavengers.

Oxyradical-mediated clastogenic plasma factors in XXXX : increase in clastogenic activity after PUVA.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammatory diseases'] @entity1569 :: ('MESH:D011565', 'Disease') :: ['psoriasis'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis'] @entity4059 :: ('MESH:D007020', 'Disease') :: ['CF', 'clastogenic factors'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity1252 :: ('MESH:D008180', 'Disease') :: ['lupus erythematosus'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia'] @entity6339 :: ('MESH:D005363', 'Chemical') :: ['Psoralen'] @entity272 :: ('MESH:D012871', 'Disease') :: ['skin disorder'] @entity224 :: ('MESH:D013481', 'Chemical') :: ['superoxide'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune reactions'] @entity7087 :: ('MESH:D045743', 'Disease') :: ['progressive systemic sclerosis']
@entity1569 :: (MESH:D011565,Disease) :: ['psoriasis']
